Bart D. V.
- Country
- The Netherlands
- Department
- Internal medicine/Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of Regorafenib, Vemurafenib, and Dacomitinib in Advanced Solid Tumors, Multiple Myeloma, and Non-Hodgkin Lymphoma with Targetable Genomic Variants
- Phase IIb Randomized Trial of Carboplatin-Cyclophosphamide vs. Paclitaxel ± Atezolizumab in Advanced Triple Negative Breast Cancer
Data & Insights
Has run more than one trial at 54 of 244 partner sites.
Specializations
Oncological Research
The investigator specializes in studying therapeutic approaches for colon carcinoma, with particular focus on post-surgical treatment strategies.
- Colon Cancer Management
- Post-Resection Care
- Stage II and III Cancer Treatment
Their research explores innovative applications of established medications in oncology care.
Preventive Medicine
The investigator focuses on recurrence prevention in cancer patients, examining long-term therapeutic interventions for improved patient outcomes.
- Cancer Recurrence Prevention
- Long-term Patient Monitoring
- Survival Rate Enhancement
Their work encompasses extended follow-up periods to evaluate treatment effectiveness.
Therapeutic Innovation
The investigator examines the application of acetylsalicylic acid in novel therapeutic contexts, particularly its potential benefits in oncology.
- Drug Repurposing
- Long-term Medication Studies
- Overall Survival Assessment
Their research explores alternative applications of common medications in cancer care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.